Data from Phase III trial of MK 5172 + MK 8742 (grazoprevir/elbasvir) in HCV published-Merck Inc

Merck Inc has announced the first data from the ongoing C-EDGE pivotal Phase III clinical trial program evaluating the investigational once-daily tablet MK 5172+MK 8742 (grazoprevir/elbasvir) in patients with or without cirrhosis who are infected with chronic hepatitis C virus (HCV) genotypes 1, 4 or 6 (GT1, 4 or 6). Patients in both the HCV infected, treatment-na�ve (C-EDGE TN), and HIV/HCV co-infected, treatment-na�ve (C-EDGE CO-INFXN) trials treated for 12 weeks achieved rates of sustained virologic response 12 weeks after the completion of treatment (SVR12) of 95 percent (299/316 and 207/218, respectively).

In addition, HCV infected, treatment-experienced patients (C-EDGE TE) treated with or without ribavirin (RBV) for 12 weeks achieved SVR12 rates of 94 percent (98/104) and 92 percent (97/105), respectively, and those treated for 16 weeks achieved SVR12 rates of 97 percent (103/106) and 92 percent (97/105), respectively. These data were presented at The International Liver Congress 2015. A paper detailing the findings of C-EDGE TN was published online in the Annals of Internal Medicine.